| Expression pattern: |
UP |
| Associated gene: |
MDM2, NFYA, FOXM1, PTK2 mRNA |
| Associated microRNA: |
- |
| Biological function: |
circPTK2 promotes NSCLC cell proliferation and tumorigenicity, inhibits cellular senescence, and acts as an oncogene in NSCLC progression. |
| Molecular mechanism: |
circPTK2 competitively binds the E3 ubiquitin ligase MDM2, reduces MDM2-mediated ubiquitination and degradation of NFYA, stabilizes NFYA, and enables NFYA to transcriptionally activate FOXM1, thereby promoting proliferation and suppressing senescence. |
| Biological pathway or process: |
proliferation (promotes); apoptosis (inhibits); ubiquitination (inhibits); other pathway/process (inhibits) |
| Detected method: |
Q
H
M
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; Actinomycin D / DRB Stability Assay; RT-qPCR; RNA-seq; Microarray; FISH / smFISH; ISH (In Situ Hybridization); IHC (Immunohistochemistry); IF (Immunofluorescence); Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RNA Pull-Down; Co-IP; ChIP / ChIP-seq; Luciferase Reporter Assay; Transfection; CCK8; EdU Staining; Colony Formation Assay; In Vivo Animal Model; Western Blot; Cohort Study; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
High circPTK2 expression is associated with larger tumour size, lymph node status, TNM stage, and poor overall survival, and circPTK2 may serve as a therapeutic target in NSCLC. |
| Description: |
circPTK2 is up-regulated in NSCLC tissues and cell lines and its high expression predicts poor overall survival. Functionally, circPTK2 promotes NSCLC proliferation and tumorigenicity while suppressing cellular senescence. Mechanistically, circPTK2 binds MDM2 to inhibit MDM2-mediated NFYA ubiquitination and degradation, stabilizing NFYA and increasing FOXM1 transcription. |
| Confidence score: |
0.9028 |